Deprogramming metabolism in pancreatic cancer with a bi-functional GPR55 inhibitor and biased β(2) adrenergic agonist

Metabolic reprogramming contributes to oncogenesis, tumor growth, and treatment resistance in pancreatic ductal adenocarcinoma (PDAC). Here we report the effects of (R,S′)-4′-methoxy-1-naphthylfenoterol (MNF), a GPR55 antagonist and biased β(2)-adrenergic receptor (β(2)-AR) agonist on cellular signa...

Descripción completa

Detalles Bibliográficos
Autores principales: Wnorowski, Artur, Dudzik, Danuta, Bernier, Michel, Wójcik, Jakub, Keijzers, Guido, Diaz-Ruiz, Alberto, Mazur, Karolina, Zhang, Yongqing, Han, Haiyong, Scheibye-Knudsen, Morten, Jozwiak, Krzysztof, Barbas, Coral, Wainer, Irving W.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8901637/
https://www.ncbi.nlm.nih.gov/pubmed/35256673
http://dx.doi.org/10.1038/s41598-022-07600-x

Ejemplares similares

Ejemplares similares